MetaVia (NASDAQ:MTVA) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of MetaVia (NASDAQ:MTVA) from a sell rating to a hold rating in a research note issued to investors on Saturday.

MTVA has been the subject of several other reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of MetaVia in a research report on Monday, December 22nd. HC Wainwright increased their price target on MetaVia from $12.00 to $40.00 and gave the stock a “buy” rating in a report on Tuesday, January 6th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, MetaVia currently has an average rating of “Hold” and a consensus price target of $36.50.

MetaVia Stock Down 5.8%

NASDAQ MTVA opened at $3.11 on Friday. The business’s fifty day simple moving average is $8.07 and its 200-day simple moving average is $8.66. The firm has a market cap of $6.84 million, a PE ratio of -0.37 and a beta of 0.27. MetaVia has a 52 week low of $2.95 and a 52 week high of $23.54.

MetaVia (NASDAQ:MTVA) last released its quarterly earnings data on Thursday, November 6th. The company reported ($1.54) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.86) by $1.32. Research analysts expect that MetaVia will post -3.9 EPS for the current year.

Institutional Trading of MetaVia

An institutional investor recently raised its position in MetaVia stock. SG Americas Securities LLC grew its holdings in MetaVia Inc. (NASDAQ:MTVA) by 44.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 60,386 shares of the company’s stock after purchasing an additional 18,506 shares during the quarter. SG Americas Securities LLC owned 0.25% of MetaVia worth $57,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 1.37% of the company’s stock.

MetaVia Company Profile

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.